GOSS has a good potential for a short squeeze. Information as of now are below: Shares Short 11.06 M Shares Short (prior month) 8.37 M Short % Of Float 22.58 % Days To Cover 16.4 Mo Over Mo % Change 32.14 %
"Alfi Announces Appointment of Ad Tech Executive Peter Bordes to its Board of Directors." www.accesswire.com I think we will be hearing some more good news from ALF before the week ends. My target price is $5.16.
Despite the recent pullback, I am still bullish on $ALGO. It will be a long run to get to my target (and there will be several pullbacks in the way) but my target price is still $1.80. $1.46 is a resistance ALGO needs to break before it makes its run.
With the new catalyst , following its trend, it is likely the price will hit $7.50. At that price, I don't expect to hold too long. COVID vaccine catalysts have a short decay time.
If the price holds above $1.46, it will start climbing again. The projection is shown. There will be some correction as the price aims for next high at $1.80.
With the recent advancements about the possible change of board members and the earnings report, finally ADVM should start its climb. The first target is $3.80.
The price stretched somehow fast but still not at the point which ALGO will increase. We are expecting a consolidation period before it can make another move. If price holds within the range in the next 1-2 days, there will probably be another run to the highs. The consolidation will provide opportunity to those who want to go long on ALGO.
AI and ML is gaining importance in every field. "Alfi, Inc. provides solutions that bring transparency and accountability to the digital out of home advertising marketplace. Since 2018, Alfi, Inc. has been developing its platform that uses artificial intelligence and machine learning to deliver targeted advertising in an ethical and privacy-conscious manner." ...
With the buy pressure on ALGO, it will most likely start testing $1.5.
OGEN has hit all time low and it is trying to bounce back. There is good potential for profit.
APPS is testing the first resistance. Seems like it will break the resistance.
I think it hit the bottom. From this point on, it will most likely move up (considering all the volume going in). Any news catalyst will easily trigger the stock. About my point about Phase 2 trial issue in an earlier post, any biopharma company has the risk of a failed Phase 2 trials and/or side-effects. That is why they do these trials, not immediately...
After breaking its potential upward moving channel, it bounced back from a support line. As of now, it is around a resistance. If it can pass and hold tomorrow, it may visit some higher values, as $19.40. If it cannot hold, then it will probably drop to about $17.2.
IBRX has broken its downward trend and trying to move up. If it can break through the resistance, it will start forming an upward moving channel.
APPS is in an upward moving channel. If it can hold, it will test the "first resistance". There is some good potential in this stock.
After their Phase 2 trial issues, the price sank like titanic. It may be the lowest price and it may be a good opportunity to go long. Analyst predictions for the company goes as high as $28.